Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Gout Therapeutics Market Growth Potential: How Will Market Size Change Through 2030?
The market for gout treatments has experienced significant expansion lately. Projections indicate a rise from $3.22 billion in 2025 to $3.59 billion in 2026, reflecting a compounded annual growth rate of 11.6%. Earlier expansion during the historical period was spurred by shifts in dietary habits, the accessibility of non-steroidal anti-inflammatory drugs (NSAIDs), a greater number of arthritis diagnoses, the availability of rheumatology services within hospitals, and advancements in pain management drug research.
The market for gout treatments is projected to experience considerable expansion over the upcoming years, reaching an estimated value of $5.6 billion by 2030. This upward trajectory is underpinned by an anticipated compound annual growth rate (CAGR) of 11.8%. Key drivers fueling this growth during the forecast period include an increasing elderly demographic, the escalating prevalence of chronic health conditions, a greater emphasis on proactive arthritis management, enhanced tools that support patient adherence to treatment, and the adoption of tailored therapeutic strategies. Furthermore, prevailing trends expected to shape this market encompass a rise in arthritis linked to lifestyle factors, a greater reliance on therapies designed to reduce uric acid levels, an expanded focus on the long-term management of chronic gout cases, growing public understanding regarding the importance of early detection, and advancements in the continuous monitoring of this condition over extended periods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12118&type=smp
Gout Therapeutics Market Demand Drivers Creating New Revenue Opportunities
The increasing prevalence of gout is anticipated to be a significant driver for the expansion of the gout therapeutics market. Gout, a form of inflammatory arthritis, is characterized by discomfort and joint swelling. Factors such as obesity and metabolic syndrome are increasingly contributing to this condition by elevating uric acid levels in the bloodstream, which subsequently leads to the crystallization of urates within the joints. Therapies for gout aim to mitigate the frequency and intensity of gout symptoms by decreasing uric acid concentrations, controlling inflammation, and averting acute attacks. Evidence from PubMed Central in June 2025 suggests that gout incidence and prevalence rates, adjusted for age, are predicted to climb further by 2050, highlighting a growing global health challenge. Furthermore, data from the National Library of Medicine (NLM) in June 2024 indicates that in the United States, the number of individuals with both gout and chronic kidney disease (CKD) was 7.9 million in 2023, with projections showing a 29% increase to 9.6 million by 2035 under a standard projection. Consequently, the escalating rate of gout diagnoses is fueling the growth within the gout therapeutics sector.
Gout Therapeutics Market Segment Landscape And Growth Potential
The gout therapeutics market covered in this report is segmented –
1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics
2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication
3) By Disease Condition: Acute, Chronic
4) By End-Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors
2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids
3) By Diuretics: Thiazide Diuretics, Loop Diuretics
Gout Therapeutics Market Trends Driving Strategic Industry Expansion
Key players within the gout therapeutics sector are actively engaged in pioneering novel treatments, specifically focusing on urate transporters responsible for facilitating the reabsorption of uric acid from the urinary system back into the bloodstream; these transporters function as proteins that aid in the translocation of uric acid across cellular boundaries in the renal or intestinal tissues, thereby contributing to the regulation of circulating uric acid concentrations. As an illustration, in July of 2025, Eisai Co. Ltd., a pharmaceutical entity headquartered in Japan, introduced URECE (dotinurad), a specialized inhibitor targeting urate transporter 1 (URAT1), which is now being marketed as part of Eisai’s international specialty care offerings. This medication, URECE, is prescribed for the management of hyperuricemia linked to gout, functioning to reduce uric acid levels in the blood by enhancing its clearance through the kidneys, and it additionally presents a commendable safety record with negligible unintended effects, alongside demonstrated effectiveness in individuals experiencing mild to moderate kidney dysfunction, positioning it as a viable option for a diverse patient population suffering from gout.
Gout Therapeutics Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC
Access The Complete Gout Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report
Gout Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
